Please provide your email address to receive an email when new articles are posted on . CHICAGO — A Fas inhibitor showed strong efficacy signals and demonstrated in patients with more than 8 days of ...
ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...
ANN ARBOR, Mich., Jan. 23, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results